Priority Review acceptance in a third large indication significantly de-risks the near-term regulatory path for mitapivat. With ~2.2B market cap and existing commercial revenue from two approved indications, approval by November 2026 would expand the addressable patient base dramatically and is a strong positive catalyst. Look for potential AdCom and any milestone-focused investor events ahead of the PDUFA date.
Price Chart
Executive Summary
Agios announced FDA Priority Review acceptance of its sNDA for mitapivat in sickle cell disease, with a PDUFA goal date of November 1, 2026. The submission is under the accelerated approval pathway based on the RISE UP Phase 2/3 trials. If approved, mitapivat would become the first oral PK activator for sickle cell disease, addressing a large underserved population and adding a third label expansion to the existing PK deficiency and thalassemia approvals.
Key Facts
- FDA accepted sNDA for mitapivat in sickle cell disease with Priority Review
- PDUFA goal date set for November 1, 2026
- Submitted under accelerated approval pathway
- Based on RISE UP Phase 2 and Phase 3 trial data (n=207 randomized 2:1)
- Mitapivat already approved in the U.S. for PK deficiency (2022) and thalassemia (2025)
- Confirmatory REIGNITE Phase 3 trial (n=159, randomized 2:1) is ongoing
Financial Impact
Potential upcoming label expansion for mitapivat in an estimated 100,000+ U.S. sickle cell patient population, incremental peak sales opportunity likely in the several hundred million dollars annually
Risk Factors
- Accelerated approval requires confirmatory trial to maintain approval; REIGNITE failure would jeopardize the label
- Competition from other sickle cell therapies (e.g., voxelotor, crizanlizumab, gene therapies/exa-cel)
- Safety boxed warning on AQVESME (thalassemia) could complicate a broad sickle cell label
- Future prescribing restrictions under AQVESME REMS may limit utilization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3323022 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 144 | $37.19 | awaiting T+60 | — | $38.05 (+2.31%) |
Aug 6, 2026 11w ago | Institutional Cluster | $31.95 | awaiting T+60 | — | $38.05 (+19.09%) |
Jul 30, 2026 12w ago | 8-K | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $38.05 (+16.18%) |
Jul 30, 2026 12w ago | Press Release | $32.75 $37.00 | ▲ +12.98% | ▲ +10.51% | $38.05 (+16.18%) |
Jul 7, 2026 15w ago | Press Release | $44.01 $33.25 | ▼ −24.45% | ▼ −26.44% | $38.05 (−13.54%) |
Jun 29, 2026 17w ago | Press Release | $38.04 $34.97 | ▼ −8.07% | ▼ −12.46% | $38.05 (+0.03%) |
Jun 18, 2026 18w ago | 8-K | $35.10 $32.81 | ▼ −6.52% | ▼ −8.27% | $38.05 (+8.40%) |
Jun 13, 2026 19w ago | Press Release | $31.82 $34.63 | ▲ +8.83% | ▲ +7.83% | $38.05 (+19.58%) |
Jun 1, 2026 21w ago | Press Release | $28.00 $33.90 | ▲ +21.07% | ▲ +19.84% | $38.05 (+35.89%) |
May 29, 2026 21w ago | Press Release | $29.40 $32.64 | ▼ −11.02% | ▼ −9.84% | $38.05 (−29.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers